Recent Updates
Recently added Catalysts
HCM Neutral Sentiment Score: 60/100

Vesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ - Fri day, March 14 , 202 5 : HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performanc

Key Takeaway: HUTCHMED (China) Limited has announced the vesting of non-performance based awards under its Long Term Incentive Plan for Dr. Weiguo Su, the company's Chief Executive Officer. On March 13, 2025, he was vested with 19,913 American depositary shares. This announcement complies with UK Market Abuse Regulation requirements and marks an important milestone in the company's compensation structure for key executives.

Market Sentiment Analysis

POSITIVE FACTORS

  • Dr. Weiguo Su, a key executive, has received a significant number of shares as part of the LTIP.
  • This vesting indicates adherence to the structured incentive framework within HUTCHMED.

Full Press Release Details

Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ - Friday, March 14, 2025: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan ("LTIP") on March 13, 2024 to the following person discharging managerial responsibilities were vested on March 13, 2025:-
Award Holder Number of American depositary shares ("ADS")
Dr Weiguo Su (Executive Director, Chief Executive Officer and Chief Scientific Officer) 19,913
The notification set out below is provided in accordance with the requirements of the UK Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Dr Weiguo Su
2 Reason for the notification
a) Position/status Executive Director, Chief Executive Officer and Chief Scientific Officer
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name HUTCHMED (China) Limited
b) LEI 2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument Identification code Ordinary Shares of US$0.10 Ordinary Share with DI ISIN: KYG4672N1016
b) Nature of the transaction Vesting of awards granted on March 13, 2024 under HUTCHMED's LTIP
c) Price(s) and volume(s)
Price(s) Volume(s)
Nil 19,913 ordinary shares
d) Aggregated information - Aggregated volume - Price N/A
e) Date of the transaction 2025-03-13
f) Place of the transaction Outside a trading venue
Investor Enquiries +852 2121 8200 / ir@hutch-med.com
Media Enquiries
FTI Consulting - +44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Alex Shaw +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
Brunswick - Zhou Yi +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Panmure Liberum Nominated Advisor and Joint Broker
Atholl Tweedie / Freddy Crossley / Rupert Dearden +44 20 7886 2500
HSBC Joint Broker
Simon Alexander / Alina Vaskina / Arnav Kapoor +44 20 7991 8888
Cavendish Joint Broker
Geoff Nash / Nigel Birks +44 20 7220 0500

Frequently Asked Questions

What awards were vested under the LTIP?

Non-performance based awards granted on March 13, 2024, were vested.

Who is the award holder for the vested shares?

Dr. Weiguo Su, the CEO and Chief Scientific Officer, held the awards.

How many ADS were vested to Dr. Weiguo Su?

A total of 19,913 American depositary shares were vested.

When did the vesting of awards occur?

The vesting took place on March 13, 2025.

What is HUTCHMED's official notification regarding?

It complies with the UK Market Abuse Regulation requirements.

Last updated: Mar 14, 2025